TLC - Taiwan Liposome Company, Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
5.85
-0.08 (-1.35%)
At close: 11:47AM EST
Stock chart is not supported by your current browser
Previous Close5.93
Open5.85
Bid5.66 x 1000
Ask6.40 x 1100
Day's Range5.82 - 6.21
52 Week Range5.02 - 11.00
Volume4,754
Avg. Volume10,484
Market Cap191.486M
Beta (3Y Monthly)0.41
PE Ratio (TTM)N/A
EPS (TTM)-0.51
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.00
Trade prices are not sourced from all markets
  • GlobeNewswire22 days ago

    TLC Appoints George Spencer-Green, MD, MS, as Chief Medical Officer

    Taiwan Liposome Company, Ltd. (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in osteoarthritis, pain management, ophthalmology and oncology, today announced the appointment of George Spencer-Green, MD, MS, as TLC’s new Chief Medical Officer. With more than three decades of clinical medicine and drug development experience, Dr. Spencer-Green will serve as a member of the TLC Management Team and guide the company in its clinical and regulatory activities.

  • GlobeNewswire24 days ago

    EMA Grants Orphan Drug Designation to TLC178 for the Treatment of Soft Tissue Sarcoma

    Taiwan Liposome Company, Ltd. (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in pain management, ophthalmology and oncology, today announced that the European Medicines Agency (EMA) has granted orphan drug designation for TLC178 for the treatment of soft tissue sarcoma. Soft tissue sarcomas are cancers of the body's connective or supportive tissues, such as cartilage, fat, muscle, fibrous tissue, and blood vessels.

  • GlobeNewswire3 months ago

    TLC to Attend Goldman Sachs Asia Pacific Healthcare Forum 2018

    TAIPEI, Taiwan and SOUTH SAN FRANCISCO, Calif., Nov. 25, 2018 -- Taiwan Liposome Company, Ltd. (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company.

  • GlobeNewswire3 months ago

    TLC Announces Pricing of Initial Public Offering of American Depositary Shares (ADSs) on Nasdaq

    TAIPEI, Taiwan and SOUTH SAN FRANCISCO, Calif., Nov. 21, 2018 -- Taiwan Liposome Company, Ltd. (4152.TWO) (TLC), a clinical-stage specialty pharmaceutical company dedicated to.